Oncology

New treatments show promise harnessing the immune system to attack late-stage skin cancer.

Trametinib targets a type of immune cell that inhibits T cell response in cancer.

Top news of the day from across the health care landscape.

A novel drug used in combination with radiation found to be a more effective treatment for prostate cancer.

About 1 in 6 women diagnosed with breast cancer have a symptom other than a lump.

New findings show that treatment with cabozantinib decreased mortality risk by 20% in patients with metastatic kidney cancer.

Increased levels of tumor-associated myeloid cells reduce cancer cell sensitivity to treatments.

Women who display non-lump breast cancer symptoms are less likely to seek needed care.

Determining the contents of extracellular vesicles may create targeted treatments.

Tailored dose-dense chemotherapy did not statistically improve recurrence-free survival in breast cancer patients.

Top news of the week in oncology and cancer drug development.

A more personalized surveillance approach may help catch melanomas in high-risk patients.

Gene therapy stimulates blood vessel growth in the heart to avoid cancer drug side effects.

Targeting a certain antioxidant protein reduces the aggressiveness of triple-negative breast cancer and increases its sensitivity to conventional anti-cancer drugs.

IL-1 antagonists are traditionally used to treat patients with rheumatoid diseases.

Targeted personalized therapy in patients with diabetes can reduce the risk of developing cancer.

Surprising findings from a study revealed that losing weight may not help protect against liver and colon cancer.

The imCORE Network Aims to advance cancer immunotherapy drugs.

RAS proteins inhibited by the newly created NS1 monobody.

Two existing drugs, Gemcitabine and DON, target the degradation of nucleotides in the liver.

Top news of the week in oncology and cancer drug development.

Promising data on pediatric relapsed/refractory acute lymphoblastic leukemia to be presented.

Top news of the day from across the health care landscape.

Collaboration will examine potential opportunities for combining daratumumab and carfilzomib for the treatment of cancer.

Combination immunotherapy more successful in treating advanced skin cancer.

Ibrance has received approval from the European Commission to treat metastatic breast cancer.

Top news of the day from across the health care landscape.

CD98 molecule could be a potential therapeutic target in AML.